Our Insights Oncology Anthony Iannacci 8/18/26 Oncology Anthony Iannacci 8/18/26 Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved Read More Oncology Anthony Iannacci 2/13/26 Oncology Anthony Iannacci 2/13/26 Keytruda Grabs its 42nd Approval in PD-L1+ PROC Read More Want to get in touch? Click here
Oncology Anthony Iannacci 8/18/26 Oncology Anthony Iannacci 8/18/26 Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved Read More
Oncology Anthony Iannacci 2/13/26 Oncology Anthony Iannacci 2/13/26 Keytruda Grabs its 42nd Approval in PD-L1+ PROC Read More
